ArticleCell transplantation2010
Delivery of a therapeutic protein by immune-privileged Sertoli cells.
Article in Cell transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Testicular immunity.Molecular aspects of medicine · 2024Review
- Time-efficient germ cell transplantation from goldfish (Animal reproduction · 2024Article
- Immunoregulatory Sertoli Cell Allografts Engineered to Express Human Insulin Survive Humoral-Mediated Rejection.International journal of molecular sciences · 2022Article
- Mouse Sertoli Cells Inhibit Humoral-Based Immunity.International journal of molecular sciences · 2022Article
- Sertoli Cell Immune Regulation: A Double-Edged Sword.Frontiers in immunology · 2022Review
- C-Peptide as a Therapy for Type 1 Diabetes Mellitus.Biomedicines · 2021Review
- Characterization of rodent Sertoli cell primary cultures.Molecular reproduction and development · 2020Review
- Exogenous Gonadotrophin Stimulation Induces Partial Maturation of Human Sertoli Cells in a Testicular Xenotransplantation Model for Fertility Preservation.Journal of clinical medicine · 2020Article
- Sertoli Cells Engineered to Express Insulin to Lower Blood Glucose in Diabetic Mice.DNA and cell biology · 2018Article
- Sertoli Cells Loaded with Doxorubicin in Lipid Micelles Reduced Tumor Burden and Dox-Induced Toxicity.Cell transplantation · 2017Article
- An overview of a Sertoli cell transplantation model to study testis morphogenesis and the role of the Sertoli cells in immune privilege.Environmental epigenetics · 2017Review
- Review
- Hair follicle dermal sheath derived cells improve islet allograft survival without systemic immunosuppression.Journal of immunology research · 2015Article
- Adult stem cell transplantation: is gender a factor in stemness?International journal of molecular sciences · 2014Review
- Sustained expression of insulin by a genetically engineered sertoli cell line after allotransplantation in diabetic BALB/c mice.Biology of reproduction · 2014Article
- Nondividing, postpubertal rat sertoli cells resumed proliferation after transplantation.Biology of reproduction · 2014Article
- The battle of the sexes for stroke therapy: female- versus male-derived stem cells.CNS & neurological disorders drug targets · 2013Review
- Germ cell transplantation as a potential biotechnological approach to fish reproduction.Fish physiology and biochemistry · 2013Review
- Genetically engineered immune privileged Sertoli cells: A new road to cell based gene therapy.Spermatogenesis · 2012Article
- The continued promise of stem cell therapy in regenerative medicine.Medical science monitor : international medical journal of experimental and clinical research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Immune-privileged Sertoli cells survive long term after allogeneic or xenogeneic transplantation without the use of immunosuppressive drugs, suggesting they could be used as a vehicle to deliver therapeutic proteins. As a model to test this, we engineered Sertoli cells to transiently produce basal levels of insulin and then examined their ability to lower blood glucose levels after transplantation into diabetic SCID mice. Mouse and porcine Sertoli cells transduced with a recombinant adenoviral vector containing furin-modified human proinsulin cDNA expressed insulin mRNA and secreted insulin protein. Transplantation of 5-20 million insulin-expressing porcine Sertoli cells into diabetic SCID mice significantly decreased blood glucose levels in a dose-dependent manner, with 20 million Sertoli cells decreasing blood glucose levels to 9.8 ± 2.7 mM. Similar results were obtained when 20 million insulin-positive, BALB/c mouse Sertoli cells were transplanted; blood glucose levels dropped to 6.3 ± 2.4 mM and remained significantly lower for 5 days. To our knowledge, this is the first study to demonstrate Sertoli cells can be engineered to produce and secrete a clinically relevant factor that has a therapeutic effect, thus supporting the concept of using immune-privileged Sertoli cells as a potential vehicle for gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.